Two new drugs being studied at Wash U study could help Alzheimer’s patients (Links to an external site)
Category: News
The fight against Alzheimer’s: ‘Every Minute Counts’ reveals latest developments (Links to an external site)
Alzheimer’s disease affects more than 5 million Americans. Neurologist Dr. Rudy Tanzi and Daisy Duarte, whose mother is in the final stages of Alzheimer’s, talk to Kathie Lee Gifford and Jenna Bush Hager about the new PBS documentary “Every Minute Counts,” which reveals the latest developments in the fight against the devastating illness.
The New Offensive on Alzheimer’s disease: Stop it before it Starts (Links to an external site)
Alzheimer’s-Every Minute Counts (Links to an external site)
WashU early AD initiative could yield broader clues (Links to an external site)
If intervening ahead of symptoms in Alzheimer’s disease (AD) works in people with gene mutations that predispose them to getting sick at a younger age, then it will probably work in the rest of the population, principal investigator Randall Bateman theorized to BioWorld Today, and his team at Washington University (WashU) – testing drugs provided […]
Early Alzheimer’s Gene Is A Curse For Families, A Gift For Science (Links to an external site)
Landmark Alzheimer’s prevention trial to evaluate third drug (Links to an external site)
An international study to test drugs that may prevent or delay Alzheimer’s disease is adding a third drug arm. Participants who receive the drug or placebo will be monitored for at least four years for signs of the disease.
The Alzheimer’s Laboratory (Links to an external site)
A changing landscape: Alzheimer’s disease, research and the future of care (Links to an external site)
Ongoing international research led by Washington University investigators is changing the Alzheimer’s disease landscape from hopeless to hopeful.
Eli Lilly’s Experimental Alzheimer’s Drug Fails in Large Trial (Links to an external site)
An experimental Alzheimer’s drug that had previously appeared to show promise in slowing the deterioration of thinking and memory has failed in a large Eli Lilly clinical trial, dealing a significant disappointment to patients hoping for a treatment that would alleviate their symptoms.